Home » Analysts Like Abbott’s Post-Health Reform Guidance
Analysts Like Abbott’s Post-Health Reform Guidance
Abbott Laboratories’ first-quarter profit met Wall Street expectations
on better-than-expected sales of its drug Humira, though the company lowered its profit outlook due to the impact of the health care overhaul.
Forbes
Forbes
Upcoming Events
-
07May
-
14May
-
30May